Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13529211 | 0.97 | POLB (0.56) | HSD17B2CA12CA1CA2CA7 | |
| Acetic Acid SCHEMBL28006892 | 0.96 | HSD17B2 (0.54) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL13529204 | 0.96 | HSD17B2 (0.54) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL17854640 | 0.96 | HSD17B2 (0.54) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL13529208 | 0.94 | HSD17B2 (0.52) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL13529213 | 0.94 | HSD17B2 (0.52) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL13529212 | 0.94 | HSD17B2 (0.52) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL13529209 | 0.94 | HSD17B2 (0.52) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL29524292 | 0.94 | HSD17B2 (0.62) | HSD17B2PTGER4POLBTP53RAB9A | |
| SCHEMBL5495236 | 0.94 | HSD17B2 (0.62) | HSD17B2PTGER4POLBTP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106916067-A | The preparation method of hydrochloric acid Erlotinib key intermediate | 江苏豪森药业集团有限公司 | 2017-07-04 | — | — | CN | claimed |
| CN-104725327-A | Environment-friendly method for preparing high-yield erlotinib hydrochloride | UNIV SHANDONG | 2015-06-24 | — | — | CN | claimed |
| US-8133999-B2 | Process for preparation of 6, 7-bis(2-methoxyethoxy) quinazolin-4-one | UBE INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | claimed |
| EP-1650196-B1 | PROCESS FOR PRODUCING 6,7-BIS(2-METHOXYETHOXY)-QUINAZOLIN-4-ONE | UBE INDUSTRIES (JP) | 2011-03-30 | — | — | EP | claimed |
| US-20090253909-A1 | PROCESS FOR PREPARATION OF 6, 7-BIS (2-METHOXYETHOXY) QUINAZOLIN-4-ONE | UBE INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | claimed |
| US-20060276647-A1 | Process for producing 6, 7-bis (2-methoxyethoxy)-quinazolin-4-one | UBE INDUSTRIES, LTD (JP) | 2006-12-07 | — | — | US | claimed |
| EP-1650196-A1 | PROCESS FOR PRODUCING 6,7-BIS(2-METHOXYETHOXY)-QUINAZOLIN-4-ONE | Ube Industries, Ltd. (JP) | 2006-04-26 | — | — | EP | claimed |
| EP-4686757-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | e-therapeutics PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| CN-106916067-B | Preparation method of erlotinib hydrochloride key intermediate | 江苏豪森药业集团有限公司 | 2021-07-06 | — | — | CN | disclosed |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3103799-B1 | QUINAZOLINE DERIVATIVES | OSI PHARMACEUTICALS LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0817775-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996030347-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276647-A1 | Process for producing 6, 7-bis (2-methoxyethoxy)-quinazolin-4-one | CPS1, CYP3A4, RPS27A | HSD17B2 2658/4885CA12 2015/4885CA1 442/4885 |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | HSD17B2 3511/4885CA12 4538/4885CA1 4091/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | HSD17B2 3511/4885CA12 4538/4885CA1 4091/4885 |
| US-20090253909-A1 | PROCESS FOR PREPARATION OF 6, 7-BIS (2-METHOXYETHOXY) QUINAZOLIN-4-ONE | CYP4F11, OGFR, CYP4B1 | HSD17B2 2614/4885CA12 1166/4885CA1 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.